"Self-Compassion and Self-Efficacy in Parkinson's Disease: Associations With Symptoms, Function, and Quality of Life"

"Associations of Self-Compassion and Self-Efficacy With Symptom Severity, Functional Status, and Quality of Life in Individuals With Parkinson's Disease: A Cross-Sectional Study"

The aim of this study is to evaluate the associations of self-compassion and self-efficacy levels with symptom severity, functional status, and quality of life in individuals with Parkinson's disease.

Study Overview

• Status: Not yet recruiting
• Conditions: Parkinson Disease, Symptom Severity, Functional Status, Quality of Life, Self-compassion, and Self-efficacy
• Intervention / Treatment: Other: Self-Report Questionnaire Assessment

• Study Type: Observational
• Enrollment (Estimated): 100

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: N/A

• Sampling Method: Non-Probability Sample

Study Population

The study population will consist of individuals diagnosed with Parkinson's disease who are classified as Hoehn and Yahr stage 1-3, aged between 40 and 85 years, and have sufficient cognitive function (MMSE ≥ 24). Participants will be recruited from patients attending the Movement Disorders Outpatient Clinic of the Neurology Department

Description

Inclusion Criteria:

• Clinically diagnosed Parkinson's disease

Hoehn and Yahr stage 1-3

Age between 40 and 85 years

Sufficient cognitive function to communicate (Mini-Mental State Examination [MMSE] score ≥ 24)

Patients attending the Movement Disorders Outpatient Clinic of the Neurology Department

Willingness to participate and provide informed consent

Exclusion Criteria:

• Presence of psychiatric disorders (e.g., major depression, psychotic disorders)

Diagnosis of advanced dementia

Presence of uncontrolled systemic chronic diseases (e.g., diabetes mellitus, hypertension) or severe cardiovascular or respiratory conditions

Presence of additional orthopedic or neurological conditions that may affect test performance

Severe visual or hearing impairments that could interfere with assessments

Inability to cooperate adequately with the physiotherapist during assessments

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Self-Compassion Scale (SCS) Total Score	Self-compassion will be measured using the Self-Compassion Scale (SCS), a validated self-report instrument assessing multiple dimensions of self-compassion. The total score will be calculated, with higher scores indicating greater self-compassion.	Baseline (at the time of questionnaire completion)
Self-Efficacy for Managing Chronic Disease 6-Item Scale Total Score	Self-efficacy will be measured using the Self-Efficacy for Managing Chronic Disease 6-Item Scale, a validated self-report measure. The total score will be calculated, with higher scores indicating greater perceived self-efficacy.	Baseline (at the time of questionnaire completion)
Unified Parkinson's Disease Rating Scale (UPDRS) Total Score	Symptom severity will be measured using the Unified Parkinson's Disease Rating Scale (UPDRS), a validated clinician-rated instrument assessing motor and non-motor symptoms. Higher total scores indicate greater disease severity.	Baseline (at the time of questionnaire completion)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Timed Up and Go (TUG) Test Completion Time in Seconds	Functional mobility will be measured using the Timed Up and Go (TUG) test. The time required to stand up from a chair, walk 3 meters, turn, return, and sit down will be recorded in seconds. Longer times indicate poorer functional mobility.	Baseline (at the time of questionnaire completion)
Six-Minute Walk Test (6MWT) Distance in Meters	Functional exercise capacity will be measured using the Six-Minute Walk Test (6MWT). The total distance walked in six minutes will be recorded in meters. Greater distances indicate better functional capacity.	Baseline (at the time of questionnaire completion)
Mini-Balance Evaluation Systems Test (Mini-BESTest) Total Score	Dynamic balance will be measured using the Mini-Balance Evaluation Systems Test (Mini-BESTest), a 14-item performance-based assessment. Total scores range from 0 to 28, with higher scores indicating better balance performance.	Baseline (at the time of questionnaire completion)
Parkinson's Disease Questionnaire-39 (PDQ-39) Total Score	Quality of life will be measured using the Parkinson's Disease Questionnaire-39 (PDQ-39), a validated disease-specific instrument. Total scores range from 0 to 100, with higher scores indicating poorer quality of life.	Baseline (at the time of questionnaire completion)

Collaborators and Investigators

• Sponsor: Acibadem University

Study record dates

Study Major Dates

• Study Start (Estimated): March 30, 2026
• Primary Completion (Estimated): December 30, 2026
• Study Completion (Estimated): March 30, 2027

Study Registration Dates

• First Submitted: March 18, 2026
• First Submitted That Met QC Criteria: March 18, 2026
• First Posted (Actual): March 23, 2026

Study Record Updates

• Last Update Posted (Actual): March 23, 2026
• Last Update Submitted That Met QC Criteria: March 18, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Synucleinopathies; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neurodegenerative Diseases; Movement Disorders; Parkinsonian Disorders; Basal Ganglia Diseases; Parkinson Disease
• Other Study ID Numbers: 2026-03-130

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No